Gilead Sciences Presents 96-Week Safety and Efficacy Data for Biktarvy in HIV Treatment

Gilead Sciences today presented 96-week safety and efficacy data from multiple Phase 3 trials of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in treatment-naive and virologically suppressed adults with HIV. The data showed that 92-96% of patients maintained HIV RNA below 50 copies/mL at week 96 across different patient populations.